Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 20, 2014

MorphoSys, Emergent to Develop Prostate Cancer Candidate

  • MorphoSys is teaming up with Emergent BioSolutions to jointly develop and commercialize ES414, an anti-PSMA/anti-CD3 bi-specific antibody targeting prostate cancer. MorphoSys is picking up worldwide commercialization rights excluding the U.S. and Canada; Emergent is retaining rights in those two nations. In exchange, MorphoSys is paying Emergent $20 million upfront, and Emergent will be eligible to receive milestone payments of up to $163 million.

    MorphoSys will handle 64% and Emergent 36% of the total costs. Emergent will manufacture and supply clinical material from its facilities in Baltimore, and will receive low single-digit royalties on product sales in MorphoSys' territory. MorphoSys will receive tiered royalties from mid-single digit up to 20% on product sales in Emergent's territory.

    The candidate, which will be renamed MOR209/ES414, was developed by Emergent using its ADAPTIR™ (modular protein technology) platform. The firms say MOR209/ES414 was able in preclinical trials to redirect T-cell cytotoxicity toward prostate cancer cells expressing prostate-specific membrane antigen. They are planning to start a Phase I trial evaluating the candidate in patients with metastatic castration-resistant prostate cancer within the next six months. 

    "The preclinical data suggest that the molecule has a number of potential advantages over other drug candidates [for prostate cancer]," MorphoSys's chief development officer Arndt Schottelius, M.D., Ph.D., said in a statement. "Our goal is to combine our capabilities with those of Emergent to enable the fastest possible development and commercialization of MOR209/ES414."

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »